PortfoliosLab logoPortfoliosLab logo
BNTC vs. SPRO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BNTC vs. SPRO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Benitec Biopharma Inc. (BNTC) and Spero Therapeutics, Inc. (SPRO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BNTC achieves a -8.69% return, which is significantly lower than SPRO's -5.15% return.


BNTC

1D
1.23%
1M
9.53%
YTD
-8.69%
6M
-0.40%
1Y
-15.81%
3Y*
53.77%
5Y*
-29.92%
10Y*
-28.11%

SPRO

1D
-3.07%
1M
-19.93%
YTD
-5.15%
6M
-6.75%
1Y
-26.82%
3Y*
11.37%
5Y*
-31.31%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

BNTC vs. SPRO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
BNTC
Benitec Biopharma Inc.
-8.69%6.65%291.02%11.76%-93.51%-12.67%-60.78%-66.00%-49.27%4.70%
SPRO
Spero Therapeutics, Inc.
-5.15%126.21%-29.93%-15.03%-89.19%-17.43%101.66%56.34%-47.66%-11.32%

Correlation

The correlation between BNTC and SPRO is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.24

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Nov 2, 2017

0.12

The correlation between BNTC and SPRO shifts across timeframes, from 0.12 (all time) to 0.24 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

BNTC:

$607.45M

SPRO:

$126.59M

EPS

BNTC:

-$1.13

SPRO:

$0.39

PS Ratio

BNTC:

957.27

SPRO:

2.31

PB Ratio

BNTC:

3.31

SPRO:

2.39

Total Revenue (TTM)

BNTC:

$556.00K

SPRO:

$54.77M

Gross Profit (TTM)

BNTC:

$40.00K

SPRO:

$54.51M

EBITDA (TTM)

BNTC:

-$55.66M

SPRO:

$12.49M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BNTC vs. SPRO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BNTC
BNTC Risk / Return Rank: 3131
Overall Rank
BNTC Sharpe Ratio Rank: 3131
Sharpe Ratio Rank
BNTC Sortino Ratio Rank: 3232
Sortino Ratio Rank
BNTC Omega Ratio Rank: 3232
Omega Ratio Rank
BNTC Calmar Ratio Rank: 2929
Calmar Ratio Rank
BNTC Martin Ratio Rank: 3030
Martin Ratio Rank

SPRO
SPRO Risk / Return Rank: 2020
Overall Rank
SPRO Sharpe Ratio Rank: 2222
Sharpe Ratio Rank
SPRO Sortino Ratio Rank: 2525
Sortino Ratio Rank
SPRO Omega Ratio Rank: 2424
Omega Ratio Rank
SPRO Calmar Ratio Rank: 1717
Calmar Ratio Rank
SPRO Martin Ratio Rank: 1616
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BNTC vs. SPRO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Benitec Biopharma Inc. (BNTC) and Spero Therapeutics, Inc. (SPRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BNTCSPRODifference
Sharpe ratioReturn per unit of total volatility

+0.20

Sortino ratioReturn per unit of downside risk

+0.34

Omega ratioGain probability vs. loss probability

1.01

0.96

+0.05

Calmar ratioReturn relative to maximum drawdown

-0.41

-0.68

+0.27

Martin ratioReturn relative to average drawdown

-0.67

-1.16

+0.50

BNTC vs. SPRO - Sharpe Ratio Comparison

The current BNTC Sharpe Ratio is -0.26, which is higher than the SPRO Sharpe Ratio of -0.46. The chart below compares the historical Sharpe Ratios of BNTC and SPRO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BNTC vs. SPRO - Drawdown Comparison

The maximum BNTC drawdown since its inception was -99.92%, roughly equal to the maximum SPRO drawdown of -97.46%. Use the drawdown chart below to compare losses from any high point for BNTC and SPRO.


Loading charts...

Drawdown Indicators


BNTCSPRODifference

Max Drawdown

Largest peak-to-trough decline

-99.92%

-97.46%

-2.46%

Max Drawdown (1Y)

Largest decline over 1 year

-39.10%

-39.80%

+0.70%

Max Drawdown (3Y)

Largest decline over 3 years

-68.46%

-68.89%

+0.43%

Max Drawdown (5Y)

Largest decline over 5 years

-97.41%

-97.13%

-0.28%

Max Drawdown (10Y)

Largest decline over 10 years

-99.82%

Current Drawdown

Current decline from peak

-99.46%

-89.99%

-9.47%

Average Drawdown

Average peak-to-trough decline

-88.42%

-62.42%

-26.00%

Ulcer Index

Depth and duration of drawdowns from previous peaks

23.80%

23.07%

+0.73%

Volatility

BNTC vs. SPRO - Volatility Comparison

The current volatility for Benitec Biopharma Inc. (BNTC) is 15.84%, while Spero Therapeutics, Inc. (SPRO) has a volatility of 33.20%. This indicates that BNTC experiences smaller price fluctuations and is considered to be less risky than SPRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BNTCSPRODifference

Volatility (1M)

Calculated over the trailing 1-month period

15.84%

33.20%

-17.36%

Volatility (6M)

Calculated over the trailing 6-month period

38.29%

45.15%

-6.86%

Volatility (1Y)

Calculated over the trailing 1-year period

60.76%

58.66%

+2.10%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

101.68%

152.13%

-50.45%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

132.09%

124.91%

+7.18%

Dividends

BNTC vs. SPRO - Dividend Comparison

Neither BNTC nor SPRO has paid dividends to shareholders.


PositionTTM20252024202320222021202020192018
BNTC
Benitec Biopharma Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.20%
SPRO
Spero Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

BNTC vs. SPRO - Financials Comparison

This section allows you to compare key financial metrics between Benitec Biopharma Inc. and Spero Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M202220232024202520260
258.00K
(BNTC) Total Revenue
(SPRO) Total Revenue
Values in USD except per share items

Frequently Asked Questions


BNTC and SPRO have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SPRO has higher volatility (33.20%) compared to BNTC (15.84%). In terms of maximum drawdown, BNTC dropped -99.92% vs SPRO's -97.46%.

BNTC currently has the higher Sharpe Ratio (-0.26 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BNTC and SPRO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer